{"id":"NCT01913353","sponsor":"Bavarian Nordic","briefTitle":"A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®","officialTitle":"A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03","primaryCompletion":"2017-03","completion":"2017-08","firstPosted":"2013-08-01","resultsPosted":"2019-12-05","lastUpdate":"2019-12-05"},"enrollment":440,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["18-42 Year Old Healthy Vaccinia-naïve Subjects"],"interventions":[{"type":"BIOLOGICAL","name":"MVA BN®","otherNames":["IMVAMUNE","IMVANEX"]},{"type":"BIOLOGICAL","name":"ACAM2000®","otherNames":[]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"ACTIVE_COMPARATOR"}],"summary":"To demonstrate the efficacy of MVA-BN® in terms of vaccinia-specific Plaque Reduction Neutralization Test (PRNT) antibody response and by showing that vaccination prior to administration of ACAM2000® results in an attenuated take.","primaryOutcome":{"measure":"Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT) at the Peak Visits","timeFrame":"Day 42 for Group 1 and Day 28 for Group 2","effectByArm":[{"arm":"Group 1","deltaMin":153.5,"sd":null},{"arm":"Group 2","deltaMin":79.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["South Korea"]},"refs":{"pmids":["31722150"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":220},"commonTop":["Dermatitis Contact","Upper Respiratory Tract Infection","Injection Site Erythema","Injection Site Nodule","Lymphadenopathy"]}}